louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07010692: Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Official title: Using Fractional Lasers and Tirbanibulin Ointment to Treat Keratinocyte Carcinomas
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Keratinocyte Carcinoma
Basal Cell Carcinomas
Squamous Cell Carcinoma
Skin Cancer
Keywords: Basal Cell Carcinoma
Squamous Cell Carcinoma
BCC
SCC
keratinocyte carcinoma
skin cancer
laser treatment
Lead sponsor: Bruce Robinson, MD
Sponsor class: OTHER
First posted: 2025-06-08
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.


Eligibility criteria: Inclusion Criteria: biopsy confirmed squamous and/or basal cell carcinoma not previously treated by another method.

Exclusion Criteria:

* Cannot be pregnant at the time of treatment

Primary outcomes:
measure: Clearance of skin cancer by evidence of no clinical and/or histological recurrence after 5 years.
timeFrame: From enrollment to the end of follow-up monitoring at 5 years.
Secondary outcomes:
measure: Recurrence rate/Appearance/Patient Satisfaction as compared to accepted alternatives (Surgical excision, Mohs, Electrodesiccation and curettage)
timeFrame: Ongoing review from enrollment to the end of 5 year follow-up period & also a final review at the end of 5 years for all participants.
Other outcomes:
Locations:
city: New York
country: United States
facility: Bruce Robinson, MD
state: New York
Study officials:
affiliation: Bruce Robinson, MD
name: Bruce Robinson, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Robinson BP, Nanni GM. Utilizing fractional lasers and tirbanibulin ointment to treat squamous and basal cell carcinomas. Arch Dermatol Res. 2024 Oct 14;316(10):683. doi: 10.1007/s00403-024-03423-0.
Clinical trial NCT04263792: [18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
Official title: [18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Bacterial Infections
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2020-02-11
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to study a radioactive tracer, a type of imaging drug that is injected into the body to see how it is taken up in sites of active infection using an imaging procedure called Positron Emission Tomography/Computed Tomography (PET/CT).


Eligibility criteria: Inclusion Criteria:

* At least 18 years of age
* Known or suspected bacterial infection, per clinical documentation of suspected infection (e.g. lab results, pathology results, physician progress notes, clinical symptoms of infection)
* Able to understand the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures

Exclusion Criteria:

* Antibiotic therapy with trimethoprim within 48h of the baseline PET/CT scan
* Inability to tolerate imaging procedures, in the opinion of an investigator or treating physician
* Unstable or other severe medical or psychological comorbidities that would compromise the subject's safety or successful participation in the study, in the opinion of an investigator or treating physician
* Pregnant or breast feeding patients; a urine pregnancy test will be performed in women of child-bearing potential prior to \[18F\]F-TMP injection, to confirm non-pregnant status

Primary outcomes:
measure: Understand the biodistribution of F-TMP in human patients by looking at the F-TMP uptake in PET/CT scans
timeFrame: 3 year
measure: Understanding the kinetics of uptake of [18F]F-TMP in human patients by looking at the F-TMP uptake in PET/CT scans
timeFrame: 3 years
Secondary outcomes:
measure: Compare the uptake of [18F]F-TMP in infected versus non-infected tissues using PET/CT scans.
timeFrame: 3 year
measure: Describe the change in biodistribution of uptake of [18F]F-TMP in human patients after therapy.
timeFrame: 3 year
measure: Describe the change in kinetics of uptake of [18F]F-TMP in human patients after therapy.
timeFrame: 3 year
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Daniel Pryma, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01480492: Effect of Antiviral Therapy on Host Immune in Patients With Chronic Hepatitis B Virus(HBV) Infection
Official title: Study the Effect of Nucleoside on Host Immune in Patients With CHB
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HBeAg Positive Chronic Hepatitis B Infection
Keywords: HBV
Immune
antiviral therapy
Lead sponsor: Changhai Hospital
Sponsor class: OTHER
First posted: 2011-11-29
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 66
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: During hepatitis B virus(HBV) infection host immune plays important role.Recently there are many different antiviral therapy methods.Different antiviral therapy methods showed different effector.In order to investigate whether these antiviral therapy methods especially methods directly inhibit viral replication have some effect on host immune the investigators designed these study. The investigators want to observe the change of host immune during antiviral therapy in patients with chronic HBV infection, and analyze the relationship between these changes and the antiviral effector of these drugs.


Eligibility criteria: inclusion criteria:

* 18-65 years old
* chronic HBV infection
* HBeAg positive,HBV DNA more than 10E5 IU/mL
* ALT ≥2×UTL

exclusion criteria:

* with liver cancer
* with liver failure
* pregnant

Primary outcomes:
measure: change of programmed death-1(PD-1) level of patients with chronic HBV infection during therapy
timeFrame: base line-4 weeks-12 weeks-24 weeks-end of therapy
Secondary outcomes:
measure: Decline of hepatitis B e antigen (HBeAg) level
timeFrame: base line-4weeks-12weeks-24weeks-end of therapy
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Changhai Hospital
state: Shanghai
Study officials:
affiliation: Changhai Hospital
name: Wan Mo Bin, Professor
role: STUDY_DIRECTOR
References:
citation: Li CZ, Hu JJ, Xue JY, Yin W, Liu YY, Fan WH, Xu H, Liang XS. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. World J Gastroenterol. 2014 Jul 28;20(28):9486-96. doi: 10.3748/wjg.v20.i28.9486.
Clinical trial NCT05910892: Aromatherapy and Pain
Official title: The Effect of Aromatherapy on the Incidence and Severity of Post Procedure Pain and Discomfort in Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Pain
Keywords: Intramuscular Stimulation Therapy
Trigger Point Injections
Aromatherapy
Lead sponsor: University of Washington
Sponsor class: OTHER
First posted: 2023-06-20
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: Effect of aromatherapy on pain and discomfort in patients who are receiving intramuscular stimulation therapy or trigger point injections for chronic pain.

Detailed description: The study will explore the effect of aromatherapy on pain and discomfort in patients who are receiving intramuscular stimulation therapy or trigger point injections for chronic pain. This will be a blinded study where patients will act as their own control over two treatment visits. On one visit patient will be exposed to either the aromatherapy or a placebo. On their second visit patients will be exposed to the other compound. The study will collect demographic data, pain intensity and affect, and catastrophizing information.

Eligibility criteria: Inclusion Criteria:

* Have received at least one (1) prior IMS or trigger point injection treatment with researcher
* 18 years of age or older
* English language speaker
* has completed Pain Tracker (clinic standard of care) questionnaire prior to study visit
* any analgesic medication taken must be consistent for both sessions

Exclusion Criteria:

* Non-English language speaker
* Age \<18
* Allergy to essential oils
* Asthmatic
* Patient unable to self-administer aromatherapy

Primary outcomes:
measure: Change in Acute Pain
timeFrame: Immediately after the Procedure
Secondary outcomes:
measure: Change in Overall Experience
timeFrame: Immediately after the Procedure
Other outcomes:
Locations:
Study officials:
affiliation: University of Washington
name: Heather Tick, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04651192: Neurological and Psychological Effects of Combat-Related Stress
Official title: Neurological and Psychological Effects of Combat-Related Stress
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stress Disorder, Posttraumatic
Stress, Psychological
Lead sponsor: Tel Aviv University
Sponsor class: OTHER
Collaborators: name: Medical Corps, Israel Defense Force
First posted: 2020-12-03
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Maximum age (years): 23
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy 18-year-old Israeli males.

Brief summary: The purpose of this study is to determine what is the neurological and cognitive impact of combat exposure and prolonged stress, in the form of service in the Israeli Defense Forces.

Detailed description: Attention biases in threat processing have been assigned a prominent role in the etiology and maintenance of anxiety disorders. This study aimed to characterize the mental resilience of combat soldiers, and explore the neuro-cognitive impact of prolonged stress, using eye-tracking, MRI and fMRI measurements. Participants will be assessed using questionnaires, cognitive tasks and magnetic imaging at 5 timepoints over the span of 4 years. Outcome measures will be depression, anxiety and post-traumatic scores, as well as dwell time on threat in eye-tracking paradigms tested in previous studies, and blood oxygen level-dependent (BOLD) signals in magnetic resonance imaging (MRI) measurements.

Eligibility criteria: Inclusion Criteria:

* Soldiers in the paratroopers brigade or students in Tel-Aviv University;
* A signed consent form;
* Hebrew native speakers.

Exclusion Criteria:

* A diagnosis of a neurological disorder (i.e., epilepsy, brain injury);
* Drug or alcohol abuse;
* Cannot undergo an MRI scan, due to metal implants or other metallic foreign bodies, claustrophobia, large tattoos or irremovable piercings;
* Require glasses with a number greater than 7;
* A diagnosis of psychotic or bipolar disorders.

Primary outcomes:
measure: Change from baseline - PTSD Checklist for DSM-5 (PCL-5) score
timeFrame: 4 years, from time point 1 to time point 5
measure: Neurological measures - Gray matter volume
timeFrame: 4 years, from time point 1 to time point 5
measure: Neurological measures - Functional connectivity
timeFrame: 4 years, from time point 1 to time point 5
measure: Neurological measures - Structural connectivity
timeFrame: 4 years, from time point 1 to time point 5
measure: Neurological measures - Task activations
timeFrame: 4 years, from time point 1 to time point 5
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv University
Study officials:
affiliation: Tel Aviv University
name: Yair Bar-Haim, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03390192: Noninvasive Dual-mode Stimulation Therapy for Neurorehabilitation in Stroke
Official title: Investigation for Individualized Noninvasive Neuromodulation in Neurorehabilitation of Brain Disease: Longitudinal Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Keywords: Noninvasive brain stimulation
Repetitive Transcranial Magnetic Stimulation
Transcranial Direct Current Stimulation
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2018-01-04
Enrollment: 43
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Repetitive transcranial magnetic stimulation (rTMS) or transcranial direct current stimulation (tDCS) has been used for the modulation of stroke patients' motor function by altering the cortical excitability. Recently, more challenging approaches, such as stimulation of two or more sites or use of dual modality have been studied in stroke patients. In this study, simultaneous stimulation using both inhibitory rTMS (1Hz) and anodal tDCS (dual-mode stimulation) over bilateral primary motor cortices (M1s) was investigated to compare its modulatory effects with single inhibitory rTMS stimulation in subacute stroke patients.


Eligibility criteria: Inclusion Criteria:

* First-ever stroke patients
* Subacute stage (less than 4 weeks)
* Total Fugl-Meyer Assessment (FMA) score under 84

Exclusion Criteria:

* Major active neurological disease or psychiatric disease
* A history of seizure
* Metallic implants in their brain

Primary outcomes:
measure: Fugl-Meyer Assessment score
timeFrame: 2 months post-stimulation
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
References:
citation: Lee J, Lee A, Kim H, Shin M, Yun SM, Jung Y, Chang WH, Kim YH. Different Brain Connectivity between Responders and Nonresponders to Dual-Mode Noninvasive Brain Stimulation over Bilateral Primary Motor Cortices in Stroke Patients. Neural Plast. 2019 Apr 7;2019:3826495. doi: 10.1155/2019/3826495. eCollection 2019.
Clinical trial NCT00782392: Bioavailability and Dosing of a Monosaccharide Supplement in Adults
Official title: Bioavailability and Dosing of an Oral Monosaccharide Supplement in Adults and Effects on Resting Brain Activity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Males
Keywords: Nutrition
Infant Formula
Lead sponsor: Arkansas Children's Hospital Research Institute
Sponsor class: OTHER
Collaborators: name: University of Arkansas
name: United States Department of Agriculture (USDA)
First posted: 2008-10-31
Enrollment: 15
Sex: MALE
Minimum age (years): 18
Maximum age (years): 28
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy Caucasian Males

Brief summary: We are developing an oral supplement of carbohydrates to be added to infant formulas in order to improve brain development, immune function, and overall health of infants and children. After a careful review of what is known about these sugars, there is very little information regarding their use in infants and children, although there is some information in adults and animals.

Many of these sugars have been used in a glyco-nutritional supplement in adults and children, with minimal or no reported side effects.

We are developing a custom blend of important individual sugars, and need information regarding their dosing and blood concentrations following oral intake of the carbohydrate supplement. Timed blood samples following the carbohydrate supplement will provide us with a better understanding of the most effective dose and the metabolism of these sugars in adults. This will give us the preliminary information we need for developing an oral supplement of special sugars that can be added to infant formulas to help improve brain development and immune function in infants and children.


Eligibility criteria: Inclusion Criteria:

* Caucasian (non-hispanic)
* Male
* Age 18-28
* Regularly eat breakfast
* Healthy
* BMI within normal limits (18.5 - 24.9)
* English speaking

Exclusion Criteria:

* History of smoking, more than occasional alcohol use, or drug use.
* Chronic medical diagnosis
* Medications that may interfere with the study

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Children's Nutrition Center
state: Arkansas
Study officials:
References:
Clinical trial NCT04229992: Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation
Official title: Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colorectal Cancer
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
name: National Cancer Institute (NCI)
First posted: 2020-01-18
Enrollment: 250
Sex: ALL
Minimum age (years): 40
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: Transient receptor potential melastatin 7 (TRPM7), a magnesium (Mg) -regulated chanzyme possessing both ion channel and kinase activities, has a much stronger affinity to Mg2+ than calcium (Ca)2+. We previously reported that individuals with the TRPM7 GA/AA genotype and consumed diets high in Ca:Mg ratio had an increased risk of colorectal polyps. The TRPM7 gene was also observed to possess "driver" mutations that contribute to developing multiple cancers. However, the molecular mechanism remains unclear.

To identify if the gut microbiota plays a role in this association, we will investigate whether optimizing Ca:Mg intake ratios to 2.3 altered the abundance of the microbes (e.g. associated with TRPM7 genotype and the risk of metachronous polyps) at the genus level in at least one sample type among stool, swab and tissue in a double-blind 2x2 factorial (TRPM7 genotype and Ca:Mg ratios) randomized trial (Personalized Prevention of Colorectal Cancer Trial, NCT01105169).


Eligibility criteria: Inclusion Criteria:

• Participants from the parent study (Personalized Prevention of Colorectal Cancer Trial, NCT#01105169, IRB#100106)

Exclusion Criteria:

• Participants did not provide any stool/swab/rectal biopsy sample in the parent study

Primary outcomes:
measure: Comparisons of the Changes of Genera Prevotella by Mg Treatment vs. Placebo in Rectal Mucosa, Swab and Stool Samples
timeFrame: 12 weeks
measure: Comparisons of the Changes of Genera Bacteroides by Mg Treatment vs. Placebo in Rectal Mucosa, Swab and Stool Samples
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University
name: Martha Shrubsole, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05141292: A Registry Study of Biomarkers in Mitral Valve Disease (BIOMS-MVD)
Official title: A Registry Study of Biomarkers in Mitral Valve Disease
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cardiovascular Diseases
Lead sponsor: Beijing Institute of Heart, Lung and Blood Vessel Diseases
Sponsor class: OTHER
Collaborators: name: Chinese PLA General Hospital
First posted: 2021-12-02
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with heart failure accorrding to Inclusion and exclusion criteria.

Brief summary: The registry study aims to discover the prognostic value of bio-markers in mitral valve disease

Detailed description: The purpose of this study is to investigate the prognostic value of biomarkers in mitral valve disease.Patients with confirmed diagnosis of mitral valve disease are enrolled.The primary outcome is all-cause mortality based on the death certificates. The secondary outcome is readmission for heart failure and all-cause mortality/readmission for heart failure according to the patients' medical records.

Eligibility criteria: Inclusion Criteria:

* Patients clinically diagnosed with mitral valve disease in Beijing Anzhen Hospital from April 2016 to December 2019
* The operator performs more than 25 mitral valve operations per year / the operator unit has surgeons who complete 50 operations per year

Exclusion Criteria:

* Age ≤ 18 years
* Failure to obtain medical records and ultrasound data
* Refuse follow-up

Primary outcomes:
measure: Number of death (all cause)
timeFrame: 1 years of follow-up
Secondary outcomes:
measure: Number of rehospitalizations
timeFrame: 1 years of follow-up
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Anzhen Hospital
state: Beijing
Study officials:
affiliation: The Key Laboratory of Remodeling-Related Cardiovascular Disease, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart,Lung and Blood Vessel Diseases
name: Jie Du
role: STUDY_DIRECTOR
References:
citation: Zhou N, Ji Z, Li F, Qiao B, Lin R, Jiang W, Zhu Y, Lin Y, Zhang K, Li S, You B, Gao P, Dong R, Wang Y, Du J. Machine Learning-Based Personalized Risk Prediction Model for Mortality of Patients Undergoing Mitral Valve Surgery: The PRIME Score. Front Cardiovasc Med. 2022 Apr 1;9:866257. doi: 10.3389/fcvm.2022.866257. eCollection 2022.